These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

616 related articles for article (PubMed ID: 18018373)

  • 1. Tempered enthusiasm. Drug-safety law needs more teeth, patient-safety advocates say.
    DerGurahian J
    Mod Healthc; 2007 Oct; 37(40):16. PubMed ID: 18018373
    [No Abstract]   [Full Text] [Related]  

  • 2. PDUFA reauthorization--drug safety's golden moment of opportunity?
    Hennessy S; Strom BL
    N Engl J Med; 2007 Apr; 356(17):1703-4. PubMed ID: 17435082
    [No Abstract]   [Full Text] [Related]  

  • 3. Paying for drug approvals--who's using whom?
    Avorn J
    N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M
    N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract]   [Full Text] [Related]  

  • 5. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
    O'Reilly JT
    Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
    [No Abstract]   [Full Text] [Related]  

  • 6. Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases.
    Shea LL; Hanson A; Guglielmetti TM; Levy K
    Food Drug Law J; 2007; 62(3):445-72. PubMed ID: 17915388
    [No Abstract]   [Full Text] [Related]  

  • 7. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
    Zelenay JL
    Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
    [No Abstract]   [Full Text] [Related]  

  • 8. What ails the FDA?
    Okie S
    N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660
    [No Abstract]   [Full Text] [Related]  

  • 9. The marketplace can't give us the drug safety data we need.
    Avorn J
    MedGenMed; 2007 Feb; 9(1):29. PubMed ID: 17435636
    [No Abstract]   [Full Text] [Related]  

  • 10. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
    Gitter DM
    Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
    [No Abstract]   [Full Text] [Related]  

  • 11. Bolstering the FDA's drug-safety authority.
    Schultz WB
    N Engl J Med; 2007 Nov; 357(22):2217-9. PubMed ID: 18046024
    [No Abstract]   [Full Text] [Related]  

  • 12. Ensuring the safety of genotech drugs through implied warranty theory.
    Serra WM
    Am J Law Med; 1997; 23(2-3):363-81. PubMed ID: 9262761
    [No Abstract]   [Full Text] [Related]  

  • 13. New drug law to speed scientific review.
    Nature; 1992 Oct; 359(6396):563. PubMed ID: 1406977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. US lawmakers tackle safety reforms at the FDA.
    Zwillich T
    Lancet; 2007 Jun; 369(9578):1989-90. PubMed ID: 17577942
    [No Abstract]   [Full Text] [Related]  

  • 15. Lawsuits anticipated on generic biologicals front.
    Fox JL
    Nat Biotechnol; 2003 Jul; 21(7):721-2. PubMed ID: 12833078
    [No Abstract]   [Full Text] [Related]  

  • 16. The challenges of globalization in pharmaceutical law--is an international drug approval system modeled after the European system worth considering?
    Purnhagen KP
    Food Drug Law J; 2008; 63(3):623-45. PubMed ID: 19031663
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Berry MD
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-79. PubMed ID: 23297449
    [No Abstract]   [Full Text] [Related]  

  • 19. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
    Fernandez DS; Huie JT
    Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
    [No Abstract]   [Full Text] [Related]  

  • 20. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation?
    Orlando VI
    Am J Law Med; 1999; 25(4):543-68. PubMed ID: 10629734
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 31.